Ergoteles’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Ergoteles’s Portfolio ORGS Stock Details ORGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,378	Closed	-$365K	–	1669
2021 Q3	$365K	Sell	7,378 -54	-0.7%	-$2.71K	0.01%	717
2021 Q2	$377K	Buy	+7,432	New	+$374K	0.01%	949

Other funds holding ORGS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ronit Capital London, United Kingdom $74.3M AUM 13.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BHB

Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ergoteles's ORGS Position: Q4 2021 in Review

Ergoteles sold out of Orgenesis Inc. Common Stock (ORGS) in Q4 2021, closing a stake of 7,378 shares — an estimated $365K sold.

Ergoteles first reported a position in ORGS in Q2 2021 and held it in 2 quarters. The position peaked at $377K in Q2 2021. 26 funds tracked by Wall St. Rank hold ORGS as of Q4 2021.

Ergoteles reported no remaining Orgenesis Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Ergoteles sold 7,378 Orgenesis Inc. Common Stock shares in Q4 2021, an estimated $365K.
Ergoteles first reported a position in Orgenesis Inc. Common Stock in Q2 2021 and held it in 2 quarters.
Ergoteles's Orgenesis Inc. Common Stock position peaked at $377K in Q2 2021.
26 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.